Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Yamuna Kondapally, Julie Fortier, Antony Tin, Sarah Kelley, Derrick Renner, Mark Fiala, Angel Rodriguez, Minetta Liu, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Michael Slade

Blood (2025) 146 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2025-2219

Published: 2025

Journal Articles

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Michael Slade, Mark Fiala, Julie Fortier, Sarah Kelley, David Spencer, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 2218.

https://doi.org/10.1182/blood-2025-2218

Published: 2025

Journal Articles

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Zachary Crees, Mark Schroeder, Michael Slade, Keith Stockerl-Goldstein, Ravi Vij, Ella Sorani, Irit Glicko-Kabir, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2025-5957

Published: 2025

Journal Articles

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

Michael Slade, Julie Fortier, Mark Fiala, Binod Dhakal, Hans Lee, Frank Kuhr, Wojciech Swat, Paola Tononi, Nicolo Manaresi, Alberto Ferrarini, Sarah Kelley, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij

Blood (2025) 146 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2025-5851

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Reyka G. Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie Ritchey, Jaebok Choi, Camille N. Abboud, Iskra Pusic, Meagan Jacoby, Peter Westervelt, Matthew Christopher, Amanda Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L. Uy, John F. DiPersio

Blood (2025) 145 (13): 1382–1394.

https://doi.org/10.1182/blood.2024026497

Published: 2025

Includes: Supplemental data

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Journal Articles

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Alexa Loncharich, Mark Fiala, Julie Fortier, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder, Mark Zaydman, Michael Slade, Mariya Liyasova

Blood (2024) 144 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2024-211395

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Akhil Kesaraju, Alexa Loncharich, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Ravi Vij, Michael Slade

Blood (2024) 144 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2024-208241

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Yash Shah, Mark Fiala, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Zachary D. Crees, Michael Slade

Blood (2024) 144 (Supplement 1): 3792.1.

https://doi.org/10.1182/blood-2024-209293

Published: 2024

Journal Articles

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Zachary David Crees, Keith Stockerl-Goldstein, Ella Sorani, Debby Ickowicz, Liron Darvish, John F. DiPersio

Blood (2023) 142 (Supplement 1): 5777.

https://doi.org/10.1182/blood-2023-184608

Published: 2023

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Journal Articles

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Michael Slade, Abir Khaled, Mark Fiala, Zac McDonald, Mariya Liyasova, Julie Fortier, Mark Zaydman, Sarah Kelley, Zachary David Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2023) 142 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2023-172440

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139332

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Prolonged CXCR4 Receptor Occupancy By Motixafortide Following a Single Subcutaneous Injection Is Associated with Extended Mobilization of CD34+ Cells in Peripheral Blood for > 24 Hours

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only